DFTX
DFTX clinical trials: Definium Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Definium Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
DFTX on the catalyst calendar · DFTX registry changes
- Primary completion Sep 16, 2026ActualPhase 2NCT07303907A Phase 2A Trial of DT402 for Autism Spectrum DisorderDefinium Therapeutics US, Inc. · Autism Spectrum DisorderCompletedDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 3NCT07592689A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)Definium Therapeutics US, Inc. · Major Depressive DisorderRecruitingDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2026ActualPhase 3NCT06741228A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Definium Therapeutics US, Inc. · Generalized Anxiety DisorderActive, not recruitingDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 13, 2026ActualPhase 3NCT06809595A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)Definium Therapeutics US, Inc. · Generalized Anxiety DisorderActive, not recruitingDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 20, 2026ActualPhase 3NCT06941844A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)Definium Therapeutics US, Inc. · Major Depressive DisorderActive, not recruitingDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2023ActualPhase 2NCT05407064A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsDefinium Therapeutics US, Inc. · Anxiety GeneralizedCompletedDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 6, 2023ActualPhase 2NCT05200936Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept TrialDefinium Therapeutics US, Inc. · ADHDCompletedDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2021ActualPhase 1NCT04292197A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy VolunteersDefinium Therapeutics US, Inc. · AddictionCompletedDFTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2025ActualNo phase registeredNCT05753605My Experiences: Leveraging Digital Technologies to Better Understand Mental Health4YouandMe · Mental Health SymptomsCompletedDFTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner